Evogene (TA:EVGN) — Market Cap & Net Worth
Market Cap & Net Worth: Evogene (EVGN)
Evogene (TA:EVGN) has a market capitalization of $4.44 Million (ILA1.66 Billion) as of August 7, 2026. Listed on the TA stock exchange, this Israel-based company holds position #28792 globally and #422 in its home market, demonstrating a 11.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evogene's stock price ILA190.00 by its total outstanding shares 8718193 (8.72 Million). See Evogene (EVGN) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
Evogene Market Cap History: 2015 to 2026
Evogene's market capitalization history from 2015 to 2026. Data shows change from $727.37 Million to $4.44 Million (-37.77% CAGR).
Evogene Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evogene's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.00x
Evogene's market cap is 2.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $727.37 Million | $11.13 Million | -$17.21 Million | 65.36x | N/A |
| 2016 | $458.11 Million | $6.54 Million | -$19.59 Million | 70.05x | N/A |
| 2017 | $264.12 Million | $3.38 Million | -$20.84 Million | 78.12x | N/A |
| 2018 | $181.84 Million | $1.75 Million | -$20.76 Million | 104.09x | N/A |
| 2019 | $122.85 Million | $753.00K | -$19.11 Million | 163.15x | N/A |
| 2020 | $360.88 Million | $1.04 Million | -$26.21 Million | 347.00x | N/A |
| 2021 | $125.63 Million | $930.00K | -$30.45 Million | 135.09x | N/A |
| 2022 | $52.24 Million | $1.68 Million | -$29.84 Million | 31.19x | N/A |
| 2023 | $70.07 Million | $5.64 Million | -$23.88 Million | 12.42x | N/A |
| 2024 | $17.02 Million | $8.51 Million | -$16.48 Million | 2.00x | N/A |
Competitor Companies of EVGN by Market Capitalization
Companies near Evogene in the global market cap rankings as of August 7, 2026.
Key companies related to Evogene by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #546 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #570 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.83 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $768.58 |
| #546 | Argen-X | BR:ARGX | $49.55 Billion | €748.60 |
| #570 | UCB SA | BR:UCB | $47.34 Billion | €229.20 |
Evogene Historical Marketcap From 2015 to 2026
Between 2015 and today, Evogene's market cap moved from $727.37 Million to $ 4.44 Million, with a yearly change of -37.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA4.44 Million | -36.54% |
| 2025 | ILA7.00 Million | -58.87% |
| 2024 | ILA17.02 Million | -75.72% |
| 2023 | ILA70.07 Million | +34.14% |
| 2022 | ILA52.24 Million | -58.42% |
| 2021 | ILA125.63 Million | -65.19% |
| 2020 | ILA360.88 Million | +193.76% |
| 2019 | ILA122.85 Million | -32.44% |
| 2018 | ILA181.84 Million | -31.15% |
| 2017 | ILA264.12 Million | -42.35% |
| 2016 | ILA458.11 Million | -37.02% |
| 2015 | ILA727.37 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of Evogene was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.44 Million USD |
| MoneyControl | $4.44 Million USD |
| MarketWatch | $4.44 Million USD |
| marketcap.company | $4.44 Million USD |
| Reuters | $4.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more